Table 1 Study and patient characteristics – switching and discontinuation patterns among triptan users
Citation | Country (Study period) | Study type | Study name/ database | Sample | Subgroup | n | Mean age, yrs | % female |
|---|---|---|---|---|---|---|---|---|
Alam, 2018 [35] | US (2016) | Multicenter cross-sectional, Survey | MAST study | Current users | Overall | 15,133 | 43.1 | 73.0 |
Chen, 2014 [36] | Taiwan (2005-2008) | Database study | NHIR Database | Incident users | Overall | 13,951 | 41.3 | 77.0 |
Fischer, 2016 [37] | Austria (2009-2012) | Single center chart review | Outpatient clinic, U of Innsbruck | Incident users (first/new agent) | Overall | 126 | 37.2 | 88.1 |
Katic, 2011 [38] | US (2001-2005) | Database study | i3 InVision Data Mart | Incident users | Overall | 40,892 | 37.8 | 78.9 |
Lombard, 2018 [39] | US (2012-2014) | Database study | Truven MarketScan | Incident users | Overall | 124,556 | 30.0-49.0 | 81.0 |
Ng-Mak, 2012 [40] | EU (2006-2008) | Database study | IMS Disease Analyzer | Incident users | UK | 3618 | 41.3 | 75.6 |
France | 2051 | 38.9 | 75.8 | |||||
Germany | 954 | 41.6 | 78.0 | |||||
Serrano, 2013 [41] | US (2005-2009) | Multicenter prospective, Survey | AMPP study | Current users | Consistency group A | 700 | 47.3 | 89.0 |
Consistency group B | 697 | 47.2 | 88.5 | |||||
Consistency group C | 687 | 47.1 | 88.6 |